Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HemoStyp is a patented, all-natural hemostatic agent composed of neutralized oxidized regenerated cellulose. It is designed to control bleeding by rapidly absorbing exudate and promoting clot formation at the site of application. The product is used as a topical wound dressing for the management of bleeding in surgical procedures, trauma, and other situations requiring rapid hemostasis. Upon contact with blood or fluids, it transforms into a gel that aids in clotting and can be rinsed away with water after coagulation has occurred. Clinical trials have demonstrated its non-inferiority and even superiority to Surgicel (the market leader) for achieving hemostasis within minutes[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HemoStyp.